Clinical Oncology
Volume 20, Issue 5 , Pages 358-364 , June 2008

Long-term Survival and Late Toxicity after Chemoradiotherapy for Cervical Cancer — The Addenbrooke's Experience

  • L.T. Tan

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: L. T. Tan, Oncology Centre, Box 193, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK. Tel: +1223216555; Fax: +1223274409.
    • ,
  • M. Zahra

Received 20 August 2007 ,Revised 18 February 2008 ,Accepted 4 March 2008.

References 

  1. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005;(3):CD002225
  2. Lukka H, Hirte H, Fyles A, et al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer—a meta-analysis. Clin Oncol (R Coll Radiol). 2002;14(3):203–212
  3. Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, Williams CJ. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol. 2003;68(3):217–226
  4. Tan LT, Russell S, Burgess L. Acute toxicity of chemo-radiotherapy for cervical cancer: the Addenbrooke's experience. Clin Oncol (R Coll Radiol). 2004;16(4):255–260
  5. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib–IIa cervical cancer. Lancet. 1997;350(9077):535–540
  6. Rose PG, Ali S, Watkins E, et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(19):2804–2810
  7. Eifel PJ, Moughan J, Erickson B, Iarocci T, Grant D, Owen J. Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a patterns of care study. Int J Radiat Oncol Biol Phys. 2004;60(4):1144–1153
  8. International Federation of Gynecology and Obstetrics (FIGO) . 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S43–S103
  9. King M, McConkey C, Latief TN, Hartley A, Fernando I. Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects. Clin Oncol (R Coll Radiol). 2006;18(1):38–45
  10. Chen SW, Liang JA, Hung YC, et al. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications. Int J Radiat Oncol Biol Phys. 2006;66(5):1370–1377
  11. Novetsky AP, Einstein MH, Goldberg GL, et al. Efficacy and toxicity of concomitant cisplatin with external beam pelvic radiotherapy and two high-dose-rate brachytherapy insertions for the treatment of locally advanced cervical cancer. Gynecol Oncol. 2007;105(3):635–640
  12. Perez CA, Fox S, Lockett MA, et al. Impact of dose in outcome of irradiation alone in carcinoma of the uterine cervix: analysis of two different methods. Int J Radiat Oncol Biol Phys. 1991;21(4):885–898
  13. Tan LT, Jones B, Gee A, Kingston RE. An audit of the treatment of carcinoma of the uterine cervix using external beam radiotherapy and a single line source brachytherapy technique. Br J Radiol. 1997;70(840):1259–1269
  14. Khoury GG, Bulman AS, Joslin CA. Long term results of Cathetron high dose rate intracavitary radiotherapy in the treatment of carcinoma of the cervix. Br J Radiol. 1991;64(767):1036–1043
  15. Newman G. Increased morbidity following the introduction of remote afterloading, with increased dose rate, for cancer of the cervix. Radiother Oncol. 1996;39(2):97–103
  16. Crook JM, Esche BA, Chaplain G, Isturiz J, Sentenac I, Horiot JC. Dose-volume analysis and the prevention of radiation sequelae in cervical cancer. Radiother Oncol. 1987;8(4):321–332
  17. Perez CA, Camel HM, Kuske RR, et al. Radiation therapy alone in the treatment of carcinoma of the uterine cervix: a 20-year experience. Gynecol Oncol. 1986;23(2):127–140
  18. Dhadda AS, Chan S. Bilateral avascular necrosis of the hips after chemoradiotherapy for cervical cancer. Clin Oncol (R Coll Radiol). 2006;18(7):576–577
  19. Potter R, Knocke TH, Fellner C, Baldass M, Reinthaller A, Kucera H. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993–1997) compared to the preceding period in the context of ICRU 38 recommendations. Cancer Radiother. 2000;4(2):159–172
  20. Potter R, Dimopoulos J, Georg P, et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol. 2007;83(2):148–155
  21. Micha JP, Goldstein BH, Rettenmaier MA, Brown JV, John CR, Markman M. Surgery alone or surgery with a combination radiation or chemoradiation for management of patients with bulky-stage IB2 cervical carcinoma. Int J Gynecol Cancer. 2006;16(3):1147–1151
  22. Havrilesky LJ, Leath CA, Huh W, et al. Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. Gynecol Oncol. 2004;93(2):429–434
  23. Tan LT, Zahra M. Predictors of radiation response in cervix cancer. In:  Varaj HT editors. Trends in cervical cancer research. Hauppauge NY: Nova Science Publishers; 2007;p. 149–165
  24. Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol. 1995;59(1):38–44

PII: S0936-6555(08)00102-7

doi: 10.1016/j.clon.2008.03.001

Clinical Oncology
Volume 20, Issue 5 , Pages 358-364 , June 2008

Article Tools

* Image Usage & Resolution